Abstract-The mu-opioid agonist, DAGO, and the indirect GABAA antagonist, picro toxin, produced a dose-dependent increase in horizontal motor activity following injection into the nucleus accumbens that was independent of dopamine release. Injection of muscimol into the ventral pallidum antagonizes the motor stimulant effect of dopamine agonists. It was shown that muscimol abolished the locomotor stimulant effect of DAGO microinjection into the nucleus accumbens, and partially antagonized the effect of picrotoxin.
The nucleus accumbens plays a critical role in dopamine-mediated locomotion (1, 2) . In addition, stimulation of nicotinic re ceptors in the nucleus accumbens enhances locomotion, apparently by augmenting the presynaptic release of dopamine (3). A GABAergic projection from the nucleus ac cumbens to the ventral pallidum has been shown to mediate the motor stimulant re sponse following injection of dopamine or the nicotinic agonist, carbachol, into the nucleus accumbens (3-5). Thus, pretreat ment in the ventral pallidum with the GABAA agonist, muscimol, abolishes the motor re sponse elicited by intra-accumbens adminis tration of carbachol or dopamine.
from the nucleus accumbens, dopamine independent activity is also regulated by GABA neurotransmission in the ventral pallidum.
Male Sprague-Dawley rats were housed individually under a 12 hr light/dark cycle with food and water made available ad libitum. Using Equithesin-induced anesthesia, the rats were stereotaxically implanted (9) with chronic bilateral injection cannulae one mm over the nucleus accumbens (A/P, 9.0 mm; M/L, 1.7 mm; D/V, 0.0 mm, relative to the interaural line) and ventral pallidum (A/P, 7.6 mm; M/L, 2 4 mm; D/V. -1.1 mm) (see reference 13 for details of surgical pro cedures). One week following surgery, the rats were adapted to a photocell apparatus for one hr (see reference #3 for description of the behavioral apparatus).
Rats were either injected into the nucleus accumbens with saline, DAGO or picrotoxin, or in another experiment given a pretreatment microin jection of muscimol (0.02 nmole) or saline into the ventral pallidum 5 min prior to the intra-accumbens microinjection.
All micro injections were made in a volume of 0.5 i-,l/ side over 60 sec into the unrestrained rat. Following microinjection, the rats were re turned to the photocell cage, and behavior was monitored for 120 min. Each rat was given a maximum of five behavioral trials separated by a minimum 72 hr intertrial interval. Following the last behavioral trial, the rats were given an overdose of pen tobarbital, and their brains perfused with 10% formalin via intra-cardiac injection (60 ml). Coronal sections (100 ,um thick) were made of the brain, stained with cresyl violet, and cannulae placement determined according to the atlas of Paxinos and Watson (10). Of the 24 rats implanted only in the nucleus accumbens, 22 were found to have correct placement. All of the correct placements were in the medial half of the nucleus ac cumbens. Of the 16 rats implanted in both the nucleus accumbens and ventral pallidum, 15 were found to have correct placement. All of the correct placements were in the medial half of the nucleus accumbens and in the subcommissural ventral pallidum. All the data were statistically evaluated using a two way repeated measures analysis of variance, followed by a Newman-Kuels test for multiple comparisons. Figure 1 (A and B) shows the dose-response curves for DAGO and picrotoxin-induced motor activity following injection into the nucleus accumbens. The threshold dose for DAGO was 0.3 nmoles, while it was 1.0 nmoles for picrotoxin. At the highest dose of picrotoxin, mild seizure-like forepaw tremors were observed in one of the eight rats tested. While the effect of the highest dose of DAGO persisted for 105 min, the picrotoxin-induced activity endured for only 45 min after injection. Also, the onset of motor activity following DAGO was delayed by 45 or 75 min, de pending upon the dose, while the onset was immediate following picrotoxin. The dose response relationship for DAGO and picro toxin-induced motor activity is consistent with previous reports (7, 11 ) .
The motor activation following intra-ac cumbens injection of mixed mu and delta opioid receptor agonists is not blocked by peripheral or intra-accumbens pretreatment with dopamine receptor antagonists (6, 8) . Figure 1 C shows that the motor stimulant action of the mu opioid agonist, DAGO (0.3 nmoles), was not blocked by pretreatment with the dopamine receptor antagonist, haloperidol (0.1 mg/kg, i.p.), at a dose shown previously to abolish the motor stimulant response produced by dopamine or carbachol injection into the nucleus ac cumbens (3). Morgenstern et al. (7) found that the motor stimulant action of intra accumbens injection of picrotoxin was not blocked by intra-accumbens pretreatment with haloperidol, and concluded that dop amine release in the nucleus accumbens does not play a critical role in picrotoxin-induced locomotion. Figure 2 shows that pretreatment in the ventral pallidum with muscimol (0.02 nmoles) abolished the motor stimulant effect of intra-accumbens injection of DAGO (0.3 nmoles). The effect of picrotoxin was significantly attenuated by muscimol during the first 15 min after injection, afterwhich, the blockade was less effective. When the cumulative photocell counts (120 min) were examined, the antagonism of picrotoxin by muscimol was also apparent (saline=5004+ 1140, mean±S.E.M.; muscimol=4153±511; picrotoxin=17407+3229, muscimol+picro toxin=8484±2199; P<0.05, picrotoxin vs. muscimol+picrotoxin).
The motor stimu lation following intra-accumbens injection of dopamine, or pharmacological agents acting via dopamine release, is abolished by muscimol injection into the ventral pallidum (3-5). The data in this report extend this observation to include muscimol blockade of locomotion elicited independent of dopamine release in the nucleus accumbens. Con sidering the known GABA-containing pro jection from the nucleus accumbens to the ventral pallidum (12), it has been postulated that dopamine may be inhibiting the activity of this GABA projection, thereby decreasing GABA neurotransmission in the ventral pallidum (5, 13 ). The present data can be interpreted within this framework as mu opioid and GABAA receptors acting in dependent of dopamine to inhibit the same GABA efferent to the ventral pallidum. However, the fact that only a partial blockade of picrotoxin was produced by a dose of muscimol that abolished the effects of dopamine agonists, carbachol and DAGO, indicates that locomotion by picrotoxin in the nucleus accumbens may be mediated partially by neuroanatomical substrates in dependent of GABA neurotransmission in the ventral pallidum. While we and others (4, 5, 13) have interpreted the available behavioral and anatomical data to argue in favor of a role for GABAergic neurotransmission in the ventral pallidum in mediating locomotion elicited pharmacologically from the nucleus accumbens, it is possible that muscimol may be producing changes that indirectly com pete with the motor stimulant response. Although this remains possible, at the doses employed, muscimol alone does not alter motor activity, and electrolytic or excitatory amino acid lesions of the ventral pallidum abolish locomotion elicited from the nucleus accumbens, supporting a role for this structure in regulating locomotion (5) .
In summary, the present data demonstrate that regardless of the neurochemical mecha nism by which locomotion is pharmaco logically elicited from the nucleus accum bens, it can be regulated by GABA neuro transmission in the ventral pallidum.
